This consistent high performance across internal and external validation underscores the potential of miR-200a-3p, not as a standalone test, but as a synergistic enhancer of AFP, for non-invasive identification of HCC in high-risk patients with underlying CHB or cirrhosis. This evidence concerns the gene AFP and hepatocellular carcinoma.